Public health agency The US Food and Drug Administration on Wednesday announced an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19 using fingerstick blood samples.
In July 2020, the Assure COVID-19 IgG/IgM Rapid Test Device was first authorized for emergency use by certain labs to help identify individuals with antibodies to SARS-CoV-2, indicating recent or prior COVID-19 infection, added the agency.
Currently, the Assure COVID-19 IgG/IgM Rapid Test is the only FDA authorized COVID-19 POC serology test and is available by prescription only. The fingerstick blood samples can now be tested in POC settings including doctor's offices, hospitals, urgent care centres and emergency rooms.
The agency stated the Assure test is a lateral flow assay and is authorized for use with venous whole blood, serum, plasma and fingerstick whole blood. This serology POC test, unlike POC COVID-19 diagnostic tests, uses a blood sample from the fingertip to run the test.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia